beta

ALRN

Aileron Therapeutics Inc.

Alrn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-07-2018 after market close 08-07-2018 after market close 05-09-2018 04-02-2018 11-09-2017 08-10-2017
Actual EPS -0.5 -0.56 -0.52 -0.47 -0.43 -0.45
Consensus EPS -0.58 -0.52 -0.49 -0.36 -0.43
Estimated EPS -0.58 -0.52 -0.49 -0.36 -0.43
Number of Estimates 3 3 3 3 2
EPS Surprise $0.08 -$0.04 -$0.03 -$0.07 -$0.02

Stats

Summary

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides.

Market Cap: 139 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.aileronrx.com

Shares Outstanding: 14.7 Million

Float: 14.1 Million

Dividend: 0.0 (0.0%)

Beta: -179.377319

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 51.8 Thousand

Ethical Flags

Animal testing

Longest drawdown: 289 trading days

From: 2017-10-04 To: 2018-12-07

Lowest Point:

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-11-27 12:44:38:000

More news on: Arsanis, Inc., Sphere 3D Corp., Aethlon Medical, Inc., Stocks on the move, , Read more … read more...

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-11-27 12:44:38:000

More news on: Arsanis, Inc., Sphere 3D Corp., Aethlon Medical, Inc., Stocks on the move, , Read more … read more...

Healthcare & Tech dominate midday movers

via: SeekingAlpha at 2018-11-27 12:44:38:000

More news on: Arsanis, Inc., Sphere 3D Corp., Aethlon Medical, Inc., Stocks on the move, , Read more … read more...

Aileron up 14% on study collaboration with Pfizer

via: SeekingAlpha at 2018-11-27 11:42:27:000

Thinly traded nano cap Aileron Therapeutics ( ALRN +14% ) is up on more than double normal volume, albeit on turnover of only 187K shares, on the heels of its announced collaboration with Pfizer ( PFE +0.4% ) on a clinical trial evaluating the combination of lead candidate ALRN-6924 an… read more...

Aileron up 14% on study collaboration with Pfizer

via: SeekingAlpha at 2018-11-27 11:42:27:000

Thinly traded nano cap Aileron Therapeutics ( ALRN +14% ) is up on more than double normal volume, albeit on turnover of only 187K shares, on the heels of its announced collaboration with Pfizer ( PFE +0.4% ) on a clinical trial evaluating the combination of lead candidate ALRN-6924 an… read more...

Aileron up 14% on study collaboration with Pfizer

via: SeekingAlpha at 2018-11-27 11:42:27:000

Thinly traded nano cap Aileron Therapeutics ( ALRN +14% ) is up on more than double normal volume, albeit on turnover of only 187K shares, on the heels of its announced collaboration with Pfizer ( PFE +0.4% ) on a clinical trial evaluating the combination of lead candidate ALRN-6924 an… read more...

Aileron Therapeutics beats by $0.06

via: SeekingAlpha at 2018-11-07 17:03:49:000

Aileron Therapeutics (NASDAQ: ALRN ): Q3 Non-GAAP EPS of -$0.50 beats by $0.06; GAAP EPS of -$0.50 misses by $0.01 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Aileron Therapeutics beats by $0.06

via: SeekingAlpha at 2018-11-07 17:03:49:000

Aileron Therapeutics (NASDAQ: ALRN ): Q3 Non-GAAP EPS of -$0.50 beats by $0.06; GAAP EPS of -$0.50 misses by $0.01 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Aileron Therapeutics beats by $0.06

via: SeekingAlpha at 2018-11-07 17:03:49:000

Aileron Therapeutics (NASDAQ: ALRN ): Q3 Non-GAAP EPS of -$0.50 beats by $0.06; GAAP EPS of -$0.50 misses by $0.01 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Tiziana Life IPO: Phase 2 Of Development, But Expensive Shares

via: SeekingAlpha at 2018-10-23 10:40:57:000

With significant amount of clinical data showing that the drug candidates should pass Phase 1 and Phase 2 of development, Tiziana Life ( TLSA ) seems an interesting biotechnology company. With that, the companys market capitalization seems too large. Competitors of Tiziana show a marke… read more...

Tiziana Life IPO: Phase 2 Of Development, But Expensive Shares

via: SeekingAlpha at 2018-10-23 10:40:57:000

With significant amount of clinical data showing that the drug candidates should pass Phase 1 and Phase 2 of development, Tiziana Life ( TLSA ) seems an interesting biotechnology company. With that, the companys market capitalization seems too large. Competitors of Tiziana show a marke… read more...

Tiziana Life IPO: Phase 2 Of Development, But Expensive Shares

via: SeekingAlpha at 2018-10-23 10:40:57:000

With significant amount of clinical data showing that the drug candidates should pass Phase 1 and Phase 2 of development, Tiziana Life ( TLSA ) seems an interesting biotechnology company. With that, the companys market capitalization seems too large. Competitors of Tiziana show a marke… read more...

Midday Gainers / Losers (10/16/2018)

via: SeekingAlpha at 2018-10-16 12:44:53:000

Gainers: FFHL +73% . BLNK +38% . GTXI +26% . ALRN +22% . IFMK +18% . ALT +18% . HQCL +17% . NDLS +15% . SEND +15% . HMNY +15% . More news on: Fuwei Films (Holdings) Co., Ltd., Blink Charging Co., GTx, Inc., Stocks on the move, , Top stock market news, … read more...

Midday Gainers / Losers (10/16/2018)

via: SeekingAlpha at 2018-10-16 12:44:53:000

Gainers: FFHL +73% . BLNK +38% . GTXI +26% . ALRN +22% . IFMK +18% . ALT +18% . HQCL +17% . NDLS +15% . SEND +15% . HMNY +15% . More news on: Fuwei Films (Holdings) Co., Ltd., Blink Charging Co., GTx, Inc., Stocks on the move, , Top stock market news, … read more...

Midday Gainers / Losers (10/16/2018)

via: SeekingAlpha at 2018-10-16 12:44:53:000

Gainers: FFHL +73% . BLNK +38% . GTXI +26% . ALRN +22% . IFMK +18% . ALT +18% . HQCL +17% . NDLS +15% . SEND +15% . HMNY +15% . More news on: Fuwei Films (Holdings) Co., Ltd., Blink Charging Co., GTx, Inc., Stocks on the move, , Top stock market news, … read more...

Midday Gainers / Losers (09/25/2018)

via: SeekingAlpha at 2018-09-25 12:53:45:000

Gainers: EDRY +34% . OASM +32% . XOXO +26% . AGTC +26% . OXFD +19% . SONC +18% . TRT +17% . ALRN +17% . I +17% . TLRY +15% . More news on: EuroDry Ltd., Oasmia Pharmaceutical, XO Group Inc., Stocks on the move, , Top stock market news, Read more ….. read more...

Midday Gainers / Losers (09/25/2018)

via: SeekingAlpha at 2018-09-25 12:53:45:000

Gainers: EDRY +34% . OASM +32% . XOXO +26% . AGTC +26% . OXFD +19% . SONC +18% . TRT +17% . ALRN +17% . I +17% . TLRY +15% . More news on: EuroDry Ltd., Oasmia Pharmaceutical, XO Group Inc., Stocks on the move, , Top stock market news, Read more ….. read more...

Midday Gainers / Losers (09/25/2018)

via: SeekingAlpha at 2018-09-25 12:53:45:000

Gainers: EDRY +34% . OASM +32% . XOXO +26% . AGTC +26% . OXFD +19% . SONC +18% . TRT +17% . ALRN +17% . I +17% . TLRY +15% . More news on: EuroDry Ltd., Oasmia Pharmaceutical, XO Group Inc., Stocks on the move, , Top stock market news, Read more ….. read more...

Aileron Therapeutics appoints Dr. Manuel Aivado as CEO

via: SeekingAlpha at 2018-09-06 09:25:23:000

Aileron Therapeutics (NASDAQ: ALRN ) announces thatManuel Aivado, MD, PhD, has been named President and Chief Executive Officer (CEO) and is elected to its Board of Directors. More news on: Aileron Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...

Aileron Therapeutics appoints Dr. Manuel Aivado as CEO

via: SeekingAlpha at 2018-09-06 09:25:23:000

Aileron Therapeutics (NASDAQ: ALRN ) announces thatManuel Aivado, MD, PhD, has been named President and Chief Executive Officer (CEO) and is elected to its Board of Directors. More news on: Aileron Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...

Aileron Therapeutics appoints Dr. Manuel Aivado as CEO

via: SeekingAlpha at 2018-09-06 09:25:23:000

Aileron Therapeutics (NASDAQ: ALRN ) announces thatManuel Aivado, MD, PhD, has been named President and Chief Executive Officer (CEO) and is elected to its Board of Directors. More news on: Aileron Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...

Midday Gainers / Losers (08/30/2018)

via: SeekingAlpha at 2018-08-30 12:36:09:000

Gainers: REIS +32% . SIG +28% . KTWO +26% . SHOS +24% . INSY +23% . CVM +19% . DXLG +18% . PARR +18% . ALRN +18% . GALT +16% . More news on: Reis, Inc, Signet Jewelers Limited, K2M Group Holdings, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/30/2018)

via: SeekingAlpha at 2018-08-30 12:36:09:000

Gainers: REIS +32% . SIG +28% . KTWO +26% . SHOS +24% . INSY +23% . CVM +19% . DXLG +18% . PARR +18% . ALRN +18% . GALT +16% . More news on: Reis, Inc, Signet Jewelers Limited, K2M Group Holdings, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/30/2018)

via: SeekingAlpha at 2018-08-30 12:36:09:000

Gainers: REIS +32% . SIG +28% . KTWO +26% . SHOS +24% . INSY +23% . CVM +19% . DXLG +18% . PARR +18% . ALRN +18% . GALT +16% . More news on: Reis, Inc, Signet Jewelers Limited, K2M Group Holdings, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/21/2018)

via: SeekingAlpha at 2018-08-21 12:55:53:000

Gainers: TAT +21% . KOSS +21% . UXIN +18% . LLEX +17% . AGFS +16% . AGEN +16% . RNN +16% . BLFS +15% . PINC +15% . GSB +15% . Losers: SEAC -42% . NEWA -38% . SITO -17% . GRIN -13% . COCP -12% . DAKT -10% . COTY -10% . BOSC -10% . … read more...

Midday Gainers / Losers (08/21/2018)

via: SeekingAlpha at 2018-08-21 12:55:53:000

Gainers: TAT +21% . KOSS +21% . UXIN +18% . LLEX +17% . AGFS +16% . AGEN +16% . RNN +16% . BLFS +15% . PINC +15% . GSB +15% . Losers: SEAC -42% . NEWA -38% . SITO -17% . GRIN -13% . COCP -12% . DAKT -10% . COTY -10% . BOSC -10% . … read more...

Midday Gainers / Losers (08/21/2018)

via: SeekingAlpha at 2018-08-21 12:55:53:000

Gainers: TAT +21% . KOSS +21% . UXIN +18% . LLEX +17% . AGFS +16% . AGEN +16% . RNN +16% . BLFS +15% . PINC +15% . GSB +15% . Losers: SEAC -42% . NEWA -38% . SITO -17% . GRIN -13% . COCP -12% . DAKT -10% . COTY -10% . BOSC -10% . … read more...

Aileron tries to right the ship; up 21%

via: SeekingAlpha at 2018-08-20 13:13:00:000

Thinly traded nano cap Aileron Therapeutics ( ALRN +20.5% ) is up on a 4x surge in volume, albeit on turnover of only 203K shares. The stock has been mired in a two-month downtrend during which it had surrendered 2/3 of its value before today's action. More news on: Aileron Therapeutics,… read more...

Midday Gainers / Losers (08/20/2018)

via: SeekingAlpha at 2018-08-20 12:54:33:000

Gainers: SSC +66% . GRIN +48% . CMCM +20% . ALRN +19% . AGMH +15% . TLRY +15% . CRON +14% . SALM +13% . CHMA +13% . GWGH +12% . More news on: Seven Stars Cloud Group, Inc., Grindrod Shipping Holdings Ltd., Cheetah Mobile Inc., Stocks on the move, , … read more...

Aileron Therapeutics misses by $0.03

via: SeekingAlpha at 2018-08-07 16:44:24:000

Aileron Therapeutics (NASDAQ: ALRN ): Q2 EPS of -$0.56 misses by $0.03 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Aileron Therapeutics misses by $0.03

via: SeekingAlpha at 2018-08-07 16:44:24:000

Aileron Therapeutics (NASDAQ: ALRN ): Q2 EPS of -$0.56 misses by $0.03 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Aileron Therapeutics misses by $0.03

via: SeekingAlpha at 2018-08-07 16:44:24:000

Aileron Therapeutics (NASDAQ: ALRN ): Q2 EPS of -$0.56 misses by $0.03 . More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

An Integrated BioSci Rounds Report: Atara Rallied While Stellar FDA Due Diligence To Unlock Value For Innovators

via: SeekingAlpha at 2018-06-09 16:14:17:000

Envy is a really stupid sin because its the only one you could never possibly have any fun at. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 08, 2018. As usual, well elucidate notable trading analytics for the day,… read more...

An Integrated BioSci Rounds Report: Atara Rallied While Stellar FDA Due Diligence To Unlock Value For Innovators

via: SeekingAlpha at 2018-06-09 16:14:17:000

Envy is a really stupid sin because its the only one you could never possibly have any fun at. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 08, 2018. As usual, well elucidate notable trading analytics for the day,… read more...

An Integrated BioSci Rounds Report: Atara Rallied While Stellar FDA Due Diligence To Unlock Value For Innovators

via: SeekingAlpha at 2018-06-09 16:14:17:000

Envy is a really stupid sin because its the only one you could never possibly have any fun at. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 08, 2018. As usual, well elucidate notable trading analytics for the day,… read more...

An Integrated BioSci Rounds Report: Atara Rallied While Stellar FDA Due Diligence To Unlock Value For Innovators

via: SeekingAlpha at 2018-06-09 16:14:17:000

Envy is a really stupid sin because its the only one you could never possibly have any fun at. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for June 08, 2018. As usual, well elucidate notable trading analytics for the day,… read more...

3 Things In Biotech, May 23: Gene Therapy Continues To Promise

via: SeekingAlpha at 2018-05-24 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, May 23: Gene Therapy Continues To Promise

via: SeekingAlpha at 2018-05-24 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, May 23: Gene Therapy Continues To Promise

via: SeekingAlpha at 2018-05-24 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, May 23: Gene Therapy Continues To Promise

via: SeekingAlpha at 2018-05-24 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

After Hours Gainers / Losers (04/11/2018)

via: SeekingAlpha at 2018-04-11 17:34:50:000

Top gainers: QNST +20.9% . BLCM +15.3% . ALRN +4.3% . VEON +2.1% . FTI +1.4% . More news on: QuinStreet, Inc., Bellicum Pharmaceuticals, Aileron Therapeutics, Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (04/11/2018)

via: SeekingAlpha at 2018-04-11 17:34:50:000

Top gainers: QNST +20.9% . BLCM +15.3% . ALRN +4.3% . VEON +2.1% . FTI +1.4% . More news on: QuinStreet, Inc., Bellicum Pharmaceuticals, Aileron Therapeutics, Stocks on the move, , News on ETFs, Read more … read more...

Midday Gainers / Losers (04/09/2018)

via: SeekingAlpha at 2018-04-09 12:42:16:000

Gainers: AVXS +82% . KONE +59% . HEAR +29% . TRPX +24% . RGNX +22% . MEET +20% . HTBX +20% . QURE +18% . ALRN +18% . ABEO +16% . More news on: AveXis, Kingtone Wirelessinfo Solution Holding Ltd, Turtle Beach Corporation, Stocks on the move, , Read … read more...

Midday Gainers / Losers (04/09/2018)

via: SeekingAlpha at 2018-04-09 12:42:16:000

Gainers: AVXS +82% . KONE +59% . HEAR +29% . TRPX +24% . RGNX +22% . MEET +20% . HTBX +20% . QURE +18% . ALRN +18% . ABEO +16% . More news on: AveXis, Kingtone Wirelessinfo Solution Holding Ltd, Turtle Beach Corporation, Stocks on the move, , Read … read more...

Aileron Therapeutics misses by $0.01

via: SeekingAlpha at 2018-04-02 16:52:20:000

Aileron Therapeutics (NASDAQ: ALRN ): Q4 EPS of -$0.47 misses by $0.01 . Cash, cash equivalents and investments of $50.8M Press Release More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , read more...

Aileron Therapeutics misses by $0.01

via: SeekingAlpha at 2018-04-02 16:52:20:000

Aileron Therapeutics (NASDAQ: ALRN ): Q4 EPS of -$0.47 misses by $0.01 . Cash, cash equivalents and investments of $50.8M Press Release More news on: Aileron Therapeutics, Earnings news and commentary, Healthcare stocks news, , read more...

Daily Insider Ratings Round Up 1/11/18: ASPS, FLDM, CHN

via: SeekingAlpha at 2018-01-14 12:14:38:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-23 10:29:28:000

Subscription notice: You can automatically receive Stocks to Watch every week by following the SA Stocks to Watch account and setting email alerts on. More news on: Wal-Mart Stores, Inc., Target Corporation, Amazon.com, Inc., Consumer stocks news, Tech stocks news, Financial stocks ne… read more...

Stocks to watch next week

via: SeekingAlpha at 2017-08-05 09:42:29:000

Key events are scheduled for the companies listed below next week. More news on: Marriott International, Inc., CBS Corporation, Tyson Foods Inc., Consumer stocks news, Financial stocks news, Tech stocks news, Healthcare stocks news, Top Breaking stock news, Read more … read more...

Daily Insider Ratings Round Up 7/7/17: IFF, AYX, MCC, SEAS, GSAT

via: SeekingAlpha at 2017-07-10 12:01:31:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC yesterday. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Significant" in… read more...

U.S. IPO Weekly Recap: Blue Apron Breaks In A Busy Week For IPOs

via: SeekingAlpha at 2017-07-01 15:46:00:000

Eight deals priced this week, raising a combined $740 million. Meal-kit unicorn Blue Apron led the pack along with two banks, four biotechs and an enterprise storage provider. The week also saw one SPAC IPO and one Reg A+ offering. Before this week, the year's eight VC-backed tech IPOs avera… read more...

Biopharm Aileron Therapeutics' IPO Set For Thursday: We're Cautious

via: SeekingAlpha at 2017-06-27 11:04:16:000

Overview Aileron Therapeutics Inc. (Nasdaq: ALRN ) expects to raise $60M through the offer of intends to sell 3.75 million shares at a marketed price range of $15 to $17. The company has an additional 562,500 shares over-allotted as an option for its underwriters. Assuming Aileron price… read more...

Wall Street Breakfast: Google Hit With Record EU Fine

via: SeekingAlpha at 2017-06-27 07:04:43:000

Google has been slapped with a record 2.4B fine after EU antitrust regulators ruled the company had abused its power by promoting its own shopping comparison service at the top of search results. The penalty is the largest doled out by Brussels for a monopoly abuse case and… read more...

Big week for the IPO market

via: SeekingAlpha at 2017-06-27 05:03:21:000

The IPO market is expected to see more deals price this week than at any time over the past two years, as a strong stock market and the performance of new listings boosts confidence. More news on: Renaissance IPO ETF, Akcea Therapeutics, Aileron Therapeutics, IPOs, Top stock market news, N… read more...

U.S. IPO Week Ahead: Blue Apron, Biotechs And Banks

via: SeekingAlpha at 2017-06-24 07:55:40:000

Ten deals are on the IPO calendar to raise a combined $1.5 billion in the week ahead. Meal-kit delivery service Blue Apron Holdings (APRN) headlines the group, aiming to raise $480 million; five biotechs, two banks, a SPAC and an enterprise storage provider are also on deck. Read more …. read more...

Aileron Therapeutics on deck of IPO

via: SeekingAlpha at 2017-06-21 12:42:30:000

Aileron Therapeutics (Pending: ALRN ) is set for its IPO of 3.75M shares of common stock at $15 - 17. More news on: Aileron Therapeutics, Healthcare stocks news, IPOs, Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX